Shots:

• The pilot P-IIa study (RACERS) evaluating CER-001 in septic patients who are at high risk of developing acute kidney injury
• The trial met its 1EPs & 2EPs i.e., the therapy showed a direct and significant effect on endotoxin removal and reduction in the inflammatory cascade or cytokine storm, significant protective effect on endothelial functionality, reduction in renal damage, lower requirement for organ support & ICU days and improved 30-day survival
• The results were consistent with the prior published results in COVID-19 while safety and efficacy were generally consistent with historical data incl. clinical results for CER-001 in COVID-19. The company will discuss these data with regulatory authorities to develop an appropriate clinical and regulatory development strategy

Ref: Businesswire | Image: ABIONYX Pharma

Related News:- Acer Therapeutics and Relief Receive the US FDA’s CRL for ACER-001’s NDA to Treat Urea Cycle Disorders